CrossAssetDataThe Company File
···
MBX

MBX Biosciences, Inc.

MBX Biosciences, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Carmel, IN. Its latest filed balance sheet (2025-12-31) shows total assets of $453 million (its filed statements).

Pre-revenue company Pharmaceutical Preparations Carmel, IN filings since 2019 3 of 9 filed, 6 estimated
Ask the desk about MBX → Compare MBX with ZBIO → Price chart on TradingView ↗ Full EDGAR file ↗ Watch MBX →

Sector peers: ZBIOERASNKTXFULC

4.5/10headline grade
vs its business-model standard
4.2/10past 4.4/10present 4.6/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 4.5 out of ten, 3 of 9 metrics filed and 6 estimated: past 4.2 out of ten, present 4.4 out of ten, future 4.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2019. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 325 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Shareholder treatment (past): 0.3 out of ten. CrossAssetData estimate 0.3/10, confidence 35 of 100 (one part). 3rd percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 6.1 out of ten. ROE -24%: lost 24¢ per shareholder dollar. Leverage 4%: owes 4¢ per asset dollar. 61st percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 5.2 out of ten. CrossAssetData estimate 5.2/10, confidence 20 of 100 (family median). 50th percentile among 314 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Leadership (present): 1.6 out of ten. bottom 16% of 315 in its family for leadership; chief executive since 2026. 16th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 3.8 out of ten. CrossAssetData estimate 3.8/10, confidence 35 of 100 (one part). 38th percentile among 479 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Growth drivers (future): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 308 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.

The filing record

Newest annual report: Form 10-K filed 2026-03-12 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 8-K, 2026-08-27. Filings on record since 2019. Read from EDGAR 2026-10-12.

Who runs it

Hoerter, Steven L. (President and CEO); Hawryluk, P. Kent (President & CEO); Smither, John W (Chief Financial Officer); Bartram, Richard (Chief Financial Officer); Azoulay, Salomon (Chief Medical Officer); Aynechi, Tiba (director); Heron, Patrick J (director); Mathers, Edward T (director); Pescovitz, Ora H. (director); Ryder, Steven (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.